logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs

Advertise on Slator! Download the 2021 Online Media Kit Now

  • Slator Market Intelligence
  • Slator Advertising Services
  • Slator Advisory
  • Login
Search
Generic filters
Exact matches only
Advertisement
Why Now Is A Good Time to Recruit Medical Translators for Russian

5 years ago

October 28, 2015

Why Now Is A Good Time to Recruit Medical Translators for Russian

Demand Drivers ·

by Gino Diño

On October 28, 2015

5 years ago
Demand Drivers ·

by Gino Diño

On October 28, 2015

Why Now Is A Good Time to Recruit Medical Translators for Russian

Russia appears to be becoming more attractive ground for clinical trials, which may lead to more demand for language service providers active in that specific life sciences vertical. Outsourcing-Pharma reports that approved clinical trials in Russia have increased 13% in the third quarter of 2015. During that quarter, the Ministry of Health of the Russian Federation gave 203 new clinical trials the green light. 90 phase III trials have also begun, indicating a 14% increase.

Outsourcing-Pharma points to law reforms and reduced import tariffs as contributing factors that have bolstered clinical trial approvals in Russia, which has been attractive clinical research grounds for several years because its “centralized healthcare infrastructure allowed for rapid patient recruitment and retention.” The article also points out that the region hosts a large number of Good Clinical Practice certified investigating sites, and that patient recruitment typically costs 60 to 70% less compared to the US and Western Europe.

Russia currently has the most number of active clinical trials across all of North Asia: 562 out of a total of 664. The entire North Asia region, however, trails far behind areas like Europe with 13,606 trials and North America with 18,983. But according to a Pharm-Olam white paper, this actually makes the region even more competitive as there are few competing studies. This advantage along with other factors give Russia “greater cost advantages due to lower investigator fees compared to the U.S. and Western Europe.”

Advertisement

In a Market Report article for the Journal for Clinical Studies published January 2015, Igor Stefanov from contract research organization Synergy notes that despite the many benefits, “international drug developers not rush to take advantage of what we refer to as the Russian Troika Promise of Speed, Cost and Quality.” Stefanov dispelled common myths about the Russian clinical trial market: it does not have weak IP protection, the regulatory system does indeed meet international standards, and Russian sites do produce high quality data.

“Today’s Russian clinical trial market is worth $880 million and will continue to grow under any circumstances,” Stefanov said. He concluded that once drug developers dispel the myths preventing them from understanding the competitiveness of the region, “the number of international clinical trials will grow at a CAGR of 11.4%, the total number of studies will almost double by 2020, and the total clinical trial market in Russia will hit the value of $1.6 billion.”

What this all means is that international LSPs active in clinical trials with exposure to Russia or Russian within a global contract should start to experience increasing demand. LSPs looking to get in on the action need to brush up on Russian and perhaps on the 35 other official languages in various Russian Federation territories.

TAGS

clinical triallife sciencesRussia
SHARE
Gino Diño

By Gino Diño

Content strategy expert and Online Editor for Slator; father, husband, gamer, writer―not necessarily in that order.

Advertisement

SUBSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

SUBSCRIBE

SlatorSweepSlatorPro
ResearchRFP CENTER

PUBLISH

PRESS RELEASEDIRECTORY LISTING
JOB ADEVENT LISTING

Bespoke advisory including speaking, briefings and M&A

SLATOR ADVISORY
Advertisement

Featured Reports

See all
Slator 2020 Language Industry M&A and Funding Report

Slator 2020 Language Industry M&A and Funding Report

by Slator

Slator 2021 Data-for-AI Market Report

Slator 2021 Data-for-AI Market Report

by Slator

Slator 2020 Medtech Translation and Localization Report

Slator 2020 Medtech Translation and Localization Report

by Slator

Pro Guide: Sales and Marketing for Language Service Providers

Pro Guide: Sales and Marketing for Language Service Providers

by Slator

Press Releases

See all
iDISC Awarded ISO 27001 Information Security Management Certification

iDISC Awarded ISO 27001 Information Security Management Certification

by iDISC

XTRF Launches a Bi-Monthly Free Networking Event for Localization Professionals

XTRF Launches a Bi-Monthly Free Networking Event for Localization Professionals

by XTRF

150 Million Words Translated: the German EU Council Presidency Translator Sets New Records

150 Million Words Translated: the German EU Council Presidency Translator Sets New Records

by Tilde

Upcoming Events

See All
  1. Memsource MT Post-Editing Pricing Models Webinar

    Pricing Models for MT Post-Editing Workshop

    by Memsource

    · February 3

    Hear a panel of innovative localization professionals share different approaches for MT post-editing pricing.

    More info FREE

Featured Companies

See all
Text United

Text United

Memsource

Memsource

Wordbank

Wordbank

Protranslating

Protranslating

Seprotec

Seprotec

Versacom

Versacom

SDL

SDL

Smartling

Smartling

Lingotek

Lingotek

XTM International

XTM International

Smartcat

Smartcat

Translators without Borders

Translators without Borders

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Advertisement

Popular articles

Why Netflix Shut Down Its Translation Portal Hermes

Why Netflix Shut Down Its Translation Portal Hermes

by Esther Bond

The Slator 2020 Language Service Provider Index

The Slator 2020 Language Service Provider Index

by Slator

Top Language Industry Quotes of 2020

Top Language Industry Quotes of 2020

by Monica Jamieson

SlatorPod: The Weekly Language Industry Podcast

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Subscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2021 Slator. All rights reserved.

Sign up to the Slator Weekly

Join over 13,000 subscribers and get the latest language industry intelligence every Friday

Your information will never be shared with third parties. No Spam.